Pharma News

Researchers have discovered more than 275 million previously unreported genetic variants, identified from data shared by nearly 250,000 participants of the National Institutes of Health’s All of Us Research Program. Half of the genomic data are from participants of non-European genetic ancestry. The unexplored cache of variants provides researchers new pathways to better understand the genetic influences on health and disease, especially in communities who have been left out of research in the past.

Lung cancer is one of the most common cancers and has one of the lowest survival rates in the world. Cytokines, which are small signaling proteins, such as interleukin-12 (IL-12), have demonstrated considerable potential as robust tumor suppressors. However, their applications are limited due to a multitude of severe side effects.

The phase 3 clinical trial, published today in JAMA Oncology and sponsored by Polaris Pharmaceuticals, has unveiled a breakthrough in the treatment of malignant pleural mesothelioma (MPM), a rare and often rapidly fatal form of cancer associated with exposure to asbestos and which has limited therapeutic options. The trial found that a combination treatment of traditional chemotherapy with a new drug, ADI-PEG20, increased the median survival of participants by 1.6 months, and quadrupled the survival at 36 months, compared to placebo-chemotherapy.

Canadian researchers led by Montreal radiologist Gilles Soulez have developed a novel approach to treat liver tumours using magnet-guided microrobots in an MRI device.

The idea of injecting microscopic robots into the bloodstream to heal the human body is not new. It’s also not science fiction.

CDSCO releases regulatory guidelines for sampling of drugs, cosmetics & medical devices by drugs inspectors of central & state drug authorities. As per CDSCO, it will streamline and rationalize the sampling procedure of drugs, cosmetics & medical devices and maintain a centralized monthly database of Not of standard Quality (NSQ) or Spurious drugs to publish on CDSCO.

The 7th Nirma Institute of Pharmacy International Conference (NIPiCON 2024), held from February 7th to 9th, 2024, organized by the Institute of Pharmacy, Nirma University, Ahmedabad, focused on the theme "NextGen Therapeutics: Multidisciplinary Research Approaches for Drug Development and Delivery - Bridging the gaps from drug discovery to patient care”. This landmark event convened a diverse assembly of experts, scientists, and academicians from across the globe to deliberate on the latest advancements and challenges in the pharmaceutical sector.

Living organisms often create what is needed for life from scratch. For humans, this process means the creation of most essential compounds needed to survive. But not every living thing has this capability, such as the parasite that causes malaria, which affected an estimated 249 million people in 2022.

Virginia Tech researchers in the College of Agriculture and Life Sciences found that by preventing the malaria parasite from scavenging fatty acids, a type of required nutrient, it could no longer grow.

Four years after the COVID-19 pandemic began, Long COVID remains an unsolved, complex and urgent healthcare crisis. According to the Centers for Disease Control and Prevention, 1 in 9 adults in the United States who have ever had COVID-19 continue to experience Long COVID with a wide range of symptoms. Many symptoms are debilitating, affecting patients’ ability to work and go to school.

Lykos Therapeutics a company dedicated to transforming mental healthcare, announced that the U.S. Food and Drug Administration has accepted its new drug application for midomafetamine capsules used in combination with psychological intervention, which includes psychotherapy (talk therapy) and other supportive services provided by a qualified healthcare provider for individuals with post-traumatic stress disorder (PTSD). The FDA has granted the application priority review and has assigned a Prescription Drug User Fee Act target action date of August 11, 2024.